SCHEMBL8557939

SCHEMBL8557939

CC(C)C(C)CCCN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19201004 1.00
SCHEMBL10953408 0.91 NFKB1 (0.41)
SCHEMBL22872687 0.91 NFKB1 (0.41)
SCHEMBL22267421 0.88 DNM1 (0.44)
SCHEMBL20467587 0.88 DNM1 (0.44)
SCHEMBL28437674 0.88 NFKB1 (0.35)
SCHEMBL830074 0.87 NFKB1 (0.40)
Ammonia Solution, Strong SCHEMBL23581245 0.84 NFKB1 (0.38)
SCHEMBL31333176 0.81 GABRR1 (0.36)
SCHEMBL16297584 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0718260-B1 Method for working up complex amine hydrofluorides SOLVAY (BE) 1998-08-12 EP claimed
US-5728884-A REACTING WITH HALOGENATED ALKENE UNDER CONDITIONS SUCH THAT HYDROGEN FLUORIDE IN THE COMPLEX IS CONSUMED BY ADDITION TO THE HALOGENATED ALKENE SOLVAY (BE) 1998-03-17 US claimed
EP-3820846-B1 COMPOSITION FOR INHIBITING MONOMER POLYMERIZATION COMPRISING A NITROXIDE INHIBITOR, A QUINONE METHIDE RETARDER AND AN AMINE STABILIZER ECOLAB USA INC (US) 2024-01-03 EP disclosed
US-20230339866-A1 Quinazoline compounds and the use thereof in the treatment of cancer TroBio Therapeutics Pty Ltd (AU) 2023-10-26 US disclosed
US-11180578-B2 Polymerization inhibitor and retarder compositions with amine stabilizer ECOLAB USA INC. (US) 2021-11-23 US disclosed
US-20210309634-A1 COMPOSITIONS AND METHODS FOR TREATING EPIGENETIC DISEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-10-07 US disclosed
US-11123304-B2 Nanoparticles having poly(ester amide) polymer cores as drug delivery vehicles THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2021-09-21 US disclosed
US-20210143032-A1 ATOMIC LAYER ETCH AND DEPOSITION PROCESSING SYSTEMS INCLUDING A LENS CIRCUIT WITH A TELE-CENTRIC LENS, AN OPTICAL BEAM FOLDING ASSEMBLY, OR A POLYGON SCANNER LAM RESEARCH CORPORATION 2021-05-13 US disclosed
CN-112533902-A Compositions comprising nitroxide inhibitors, quinone methide blockers and amine stabilizers to inhibit polymerization of monomers 埃科莱布美国股份有限公司 2021-03-19 CN disclosed
WO-2021005586-A1 TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS NOVARTIS AG (CH) 2021-01-14 WO disclosed
WO-2020081840-A1 METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTS Magenta Therapeutics Inc. (US) 2020-04-23 WO disclosed
US-20190350870-A1 Particles as Delivery Systems NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-11-21 US disclosed
EP-3246373-B1 ORGANIC MOLECULES FOR USE AS EMITTERS CYNORA GMBH (DE) 2019-01-30 EP disclosed
EP-2859962-B1 SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND MORI KUNIO (JP) 2019-01-23 EP disclosed
EP-3246373-A1 ORGANIC MOLECULES FOR USE AS EMITTERS cynora GmbH (DE) 2017-11-22 EP disclosed
US-20140066427-A1 S1P Receptors Modulators and Their Use Thereof AKAAL PHARMA PTY LTD. (AU) 2014-03-06 US disclosed
US-5728884-A REACTING WITH HALOGENATED ALKENE UNDER CONDITIONS SUCH THAT HYDROGEN FLUORIDE IN THE COMPLEX IS CONSUMED BY ADDITION TO THE HALOGENATED ALKENE SOLVAY (BE) 1998-03-17 US disclosed